Prices delayed by at least 15 minutes | Print


NovaBay Pharmaceuticals (NBY)

Common Stock
Sell: $0.0802|Buy: $0.0804|Change: 0.01 (-9.97%)

Open 

$0.0866


Previous close 

$0.0893


Trade high 

$0.0866


Volume 

1,835,286


Year high 

$1.28


Year low 

$0.07


Dividend yield 

-


Market capitalisation 

$2.90 mn


P/E ratio 

-


ISIN 

US66987P3001


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
NovaBay Pharmaceuticals 0
More...

Company profile

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratorytested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.